203 related articles for article (PubMed ID: 16144914)
1. Estrogen-responsive finger protein as a new potential biomarker for breast cancer.
Suzuki T; Urano T; Tsukui T; Horie-Inoue K; Moriya T; Ishida T; Muramatsu M; Ouchi Y; Sasano H; Inoue S
Clin Cancer Res; 2005 Sep; 11(17):6148-54. PubMed ID: 16144914
[TBL] [Abstract][Full Text] [Related]
2. Combined Use of Immunoreactivities of RIG-I with Efp/TRIM25 for Predicting Prognosis of Patients With Estrogen Receptor-positive Breast Cancer.
Sato J; Azuma K; Kinowaki K; Ikeda K; Ogura T; Takazawa Y; Kawabata H; Kitagawa M; Inoue S
Clin Breast Cancer; 2021 Oct; 21(5):399-407.e2. PubMed ID: 33386231
[TBL] [Abstract][Full Text] [Related]
3. Efp as a primary estrogen-responsive gene in human breast cancer.
Ikeda K; Orimo A; Higashi Y; Muramatsu M; Inoue S
FEBS Lett; 2000 Apr; 472(1):9-13. PubMed ID: 10781795
[TBL] [Abstract][Full Text] [Related]
4. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth.
Urano T; Saito T; Tsukui T; Fujita M; Hosoi T; Muramatsu M; Ouchi Y; Inoue S
Nature; 2002 Jun; 417(6891):871-5. PubMed ID: 12075357
[TBL] [Abstract][Full Text] [Related]
5. Systemic distribution of estrogen-responsive finger protein (Efp) in human tissues.
Shimada N; Suzuki T; Inoue S; Kato K; Imatani A; Sekine H; Ohara S; Shimosegawa T; Sasano H
Mol Cell Endocrinol; 2004 Apr; 218(1-2):147-53. PubMed ID: 15130519
[TBL] [Abstract][Full Text] [Related]
6. Expression of estrogen-responsive finger protein (Efp) is associated with advanced disease in human epithelial ovarian cancer.
Sakuma M; Akahira J; Suzuki T; Inoue S; Ito K; Moriya T; Sasano H; Okamura K; Yaegashi N
Gynecol Oncol; 2005 Dec; 99(3):664-70. PubMed ID: 16140366
[TBL] [Abstract][Full Text] [Related]
7. Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast.
Zhang Z; Yamashita H; Toyama T; Omoto Y; Sugiura H; Hara Y; Wu X; Kobayashi S; Iwase H
Breast Cancer Res; 2003; 5(6):R250-6. PubMed ID: 14580261
[TBL] [Abstract][Full Text] [Related]
8. Nucleobindin 2 in human breast carcinoma as a potent prognostic factor.
Suzuki S; Takagi K; Miki Y; Onodera Y; Akahira J; Ebata A; Ishida T; Watanabe M; Sasano H; Suzuki T
Cancer Sci; 2012 Jan; 103(1):136-43. PubMed ID: 21988594
[TBL] [Abstract][Full Text] [Related]
9. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
[TBL] [Abstract][Full Text] [Related]
10. Increasing 14-3-3 sigma expression with declining estrogen receptor alpha and estrogen-responsive finger protein expression defines malignant progression of endometrial carcinoma.
Nakayama H; Sano T; Motegi A; Oyama T; Nakajima T
Pathol Int; 2005 Nov; 55(11):707-15. PubMed ID: 16271083
[TBL] [Abstract][Full Text] [Related]
11. Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma.
Suzuki T; Nakata T; Miki Y; Kaneko C; Moriya T; Ishida T; Akinaga S; Hirakawa H; Kimura M; Sasano H
Cancer Res; 2003 Jun; 63(11):2762-70. PubMed ID: 12782580
[TBL] [Abstract][Full Text] [Related]
12. Efp promotes in vitro and in vivo growth of endometrial cancer cells along with the activation of nuclear factor-κB signaling.
Sato W; Ikeda K; Urano T; Abe Y; Nakasato N; Horie-Inoue K; Takeda S; Inoue S
PLoS One; 2018; 13(12):e0208351. PubMed ID: 30586414
[TBL] [Abstract][Full Text] [Related]
13. Low PBRM1 identifies tumor progression and poor prognosis in breast cancer.
Mo D; Li C; Liang J; Shi Q; Su N; Luo S; Zeng T; Li X
Int J Clin Exp Pathol; 2015; 8(8):9307-13. PubMed ID: 26464681
[TBL] [Abstract][Full Text] [Related]
14. Analysis of estrogen-responsive finger protein expression in benign and malignant human breast.
Thomson SD; Ali S; Pickles L; Taylor J; Pace PE; Lymboura M; Shousha S; Coombes RC
Int J Cancer; 2001 Jan; 91(2):152-8. PubMed ID: 11146438
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the vascular endothelial growth factor and growth by estrogen and antiestrogens through Efp in Ishikawa endometrial carcinoma cells.
Dai H; Zhang P; Zhao S; Zhang J; Wang B
Oncol Rep; 2009 Feb; 21(2):395-401. PubMed ID: 19148513
[TBL] [Abstract][Full Text] [Related]
16. Expression and clinicopathological significance of oestrogen-responsive ezrin-radixin-moesin-binding phosphoprotein 50 in breast cancer.
Song J; Bai J; Yang W; Gabrielson EW; Chan DW; Zhang Z
Histopathology; 2007 Jul; 51(1):40-53. PubMed ID: 17593079
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of Efp by DNA-modified small interfering RNA inhibits breast cancer cell proliferation and in vivo tumor growth.
Ueyama K; Ikeda K; Sato W; Nakasato N; Horie-Inoue K; Takeda S; Inoue S
Cancer Gene Ther; 2010 Sep; 17(9):624-32. PubMed ID: 20467453
[TBL] [Abstract][Full Text] [Related]
18. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
Elloul S; Elstrand MB; Nesland JM; Tropé CG; Kvalheim G; Goldberg I; Reich R; Davidson B
Cancer; 2005 Apr; 103(8):1631-43. PubMed ID: 15742334
[TBL] [Abstract][Full Text] [Related]
19. Molecular cloning of rat efp: expression and regulation in primary osteoblasts.
Inoue S; Urano T; Ogawa S; Saito T; Orimo A; Hosoi T; Ouchi Y; Muramatsu M
Biochem Biophys Res Commun; 1999 Aug; 261(2):412-8. PubMed ID: 10425199
[TBL] [Abstract][Full Text] [Related]
20. Expression of E-cadherin, Snail and Hakai in epithelial cells isolated from the primary tumor and from peritumoral tissue of invasive ductal breast carcinomas.
Makdissi FB; Machado LV; Oliveira AG; Benvenuti TT; Katayama ML; Brentani MM; Osório CA; Mourão Netto M; Lyra EC; Carvalho F; Góes JC; Folgueira MA
Braz J Med Biol Res; 2009 Dec; 42(12):1128-37. PubMed ID: 19893985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
